JP2017533186A5 - - Google Patents

Info

Publication number

JP2017533186A5

JP2017533186A5 JP2017515799A JP2017515799A JP2017533186A5 JP 2017533186 A5 JP2017533186 A5 JP 2017533186A5 JP 2017515799 A JP2017515799 A JP 2017515799A JP 2017515799 A JP2017515799 A JP 2017515799A JP 2017533186 A5 JP2017533186 A5 JP 2017533186A5

Authority

JP

Japan

Prior art keywords

composition

chitosan

glycerol

composition according

weak acid

Prior art date

2015-10-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 74
• 229920001661 Chitosan Polymers 0.000 claims description 46
• 239000000203 mixture Substances 0.000 claims description 41
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 26
• 239000007864 aqueous solution Substances 0.000 claims description 18
• 239000000243 solution Substances 0.000 claims description 16
• 239000004373 Pullulan Substances 0.000 claims description 15
• 229920001218 Pullulan Polymers 0.000 claims description 15
• 235000019423 pullulan Nutrition 0.000 claims description 15
• 235000014655 lactic acid Nutrition 0.000 claims description 13
• 239000004310 lactic acid Substances 0.000 claims description 13
• 229940074404 sodium succinate Drugs 0.000 claims description 13
• ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical group [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims description 13
• 230000001954 sterilising effect Effects 0.000 claims description 10
• 238000004659 sterilization and disinfection Methods 0.000 claims description 10
• 239000003085 diluting agent Substances 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims description 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
• 238000000034 method Methods 0.000 claims 10
• 239000002253 acid Substances 0.000 claims 7
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
• 230000006196 deacetylation Effects 0.000 claims 3
• 238000003381 deacetylation reaction Methods 0.000 claims 3
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims 2
• 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
• 206010013774 Dry eye Diseases 0.000 claims 2
• 208000012659 Joint disease Diseases 0.000 claims 2
• 235000010241 potassium sorbate Nutrition 0.000 claims 2
• 239000004302 potassium sorbate Substances 0.000 claims 2
• 229940069338 potassium sorbate Drugs 0.000 claims 2
• 230000002265 prevention Effects 0.000 claims 2
• 241000222519 Agaricus bisporus Species 0.000 claims 1
• 235000001674 Agaricus brunnescens Nutrition 0.000 claims 1
• 208000035143 Bacterial infection Diseases 0.000 claims 1
• 241000233866 Fungi Species 0.000 claims 1
• 239000004367 Lipase Substances 0.000 claims 1
• 208000003251 Pruritus Diseases 0.000 claims 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
• 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
• 125000003277 amino group Chemical group 0.000 claims 1
• 230000000844 anti-bacterial effect Effects 0.000 claims 1
• 208000022362 bacterial infectious disease Diseases 0.000 claims 1
• 208000010217 blepharitis Diseases 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 230000000694 effects Effects 0.000 claims 1
• 230000007613 environmental effect Effects 0.000 claims 1
• 230000007803 itching Effects 0.000 claims 1
• 206010023332 keratitis Diseases 0.000 claims 1
• 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
• 201000008482 osteoarthritis Diseases 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 claims 1
• 230000021736 acetylation Effects 0.000 description 5
• 238000006640 acetylation reaction Methods 0.000 description 5
• 230000002538 fungal effect Effects 0.000 description 5
• 238000003756 stirring Methods 0.000 description 5
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 3
• 238000009472 formulation Methods 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
• 239000003795 chemical substances by application Substances 0.000 description 1
• 229920002674 hyaluronan Polymers 0.000 description 1
• 229960003160 hyaluronic acid Drugs 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 239000002245 particle Substances 0.000 description 1